This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New England Journal Of Medicine Releases Study Showing GSK's FluLaval Quadrivalent Vaccine Effective In Preventing Seasonal Flu In Children

PHILADELPHIA, Dec. 11, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval ® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1% [1]. This was the first large-scale clinical trial conducted specifically to review the safety and effectiveness of vaccinating children with a four-strain flu vaccine. The randomized, controlled clinical trial included 5,220 children and was one of the pivotal studies leading to the recent approval of FluLaval Quadrivalent by the U.S. Food and Drug Administration.

"The U.S. Centers for Disease Control recommends all children get vaccinated each flu season.  This is in response to how many children require flu-related medical care, and given that as many as 20,000 U.S. children are hospitalized each year due to complications of the flu," said Leonard Friedland, M.D., Vice President, Director Scientific Affairs and Public Health, GSK Vaccines North America.  "This study provides robust safety and efficacy data on FluLaval Quadrivalent, and evidence of the clinical benefit of vaccination with FluLaval Quadrivalent as demonstrated by the prevention of moderate-to-severe cases of influenza among children." 

Newly available quadrivalent flu vaccines protect against all four of the flu strains that are in circulation during a flu season.  Until this flu season, flu vaccines were limited to protecting against three influenza strains, and this necessitated the World Health Organization and other public health authorities to estimate each year what three strains might be predominant.

Virus strains that scientists refer to as A-strains traditionally cause the most cases of flu, so two A strains have been included in seasonal flu vaccines.  The other circulating strains, referred to as B-strains, derive from two distinct strain lineages.  In six of the past 11 flu seasons, the B-strain included in flu vaccines was not the predominant B-strain in circulation.  The new quadrivalent flu vaccines protect against both B strains, providing the broadest strain protection currently available.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs